- Home
- TPVG vs AVTX Comparison
TPVG vs AVTX Comparison
Compare TPVG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPVG | AVTX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TPVG | AVTX |
|---|---|---|
| Price | $5.51 | $14.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $6.38 | ★ $34.50 |
| AVG Volume (30 Days) | 386.6K | ★ 402.7K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | ★ 16.52% | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | $6.74 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $5.24 | $3.39 |
| 52 Week High | $8.20 | $20.72 |
Technical Indicators
Market Signals| Indicator | TPVG | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 47.88 |
| Support Level | $5.37 | $13.42 |
| Resistance Level | $5.79 | $16.40 |
| Average True Range (ATR) | 0.17 | 1.36 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 6.38 | 50.56 |
Price Performance
Historical ComparisonAbout TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).